Drug Profile
Nolatrexed
Alternative Names: AG 337; Nolatrexed dihydrochloride; Orataq; Thymitaq; ZX337Latest Information Update: 17 Aug 2017
Price :
$50
*
At a glance
- Originator Agouron Pharmaceuticals
- Developer Agouron Pharmaceuticals; YM BioSciences USA
- Class Quinazolines; Small molecules
- Mechanism of Action Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer; Head and neck cancer; Liver cancer; Lung cancer; Pancreatic cancer; Prostate cancer
Most Recent Events
- 09 May 2006 Eximias Pharmaceutical Corporation has been acquired by YM BioSciences
- 04 Aug 2005 Eximias presented results showing that the ETHECC trial did not meet its primary endpoint
- 22 Apr 2005 Eximias has completed enrolment in the ETHECC trial for liver cancer in Canada, Europe, South Africa and USA